A Phase 2 Trial Evaluating Safety and Tolerability of RCT2100
Phase 2
192
about 2.9 years
18–60
13 sites in AL, AZ, CA +9
About this study
Researchers are testing the safety and tolerability of a new treatment, RCT2100, in healthy people and people with cystic fibrosis. The trial will involve different doses of RCT2100 administered through inhalation, either alone or with ivacaftor.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Ivacaftor
- 3.Take RCT2100
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ivacaftor
oral (Oral Tablet)
Primary: Part 1: The number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)., Part 2: The number of participants with CF with AEs and SAEs., Part 3: The number of participants with CF with AEs and SAEs.
Respiratory